title: Impact of intra-arterial administration of boron compounds on dose-volume histograms in boron neutron capture therapy for recurrent head-and-neck tumors.
abstract: OBJECTIVE
  To analyze the dose-volume histogram (DVH) of head-and-neck tumors treated with boron neutron capture therapy (BNCT) and to determine the advantage of the intra-arterial (IA) route over the intravenous (IV) route as a drug delivery system for BNCT.
  
  
  METHODS
  Fifteen BNCTs for 12 patients with recurrent head-and-neck tumors were included in the present study. Eight irradiations were done after IV administration of boronophenylalanine and seven after IA administration. The maximal, mean, and minimal doses given to the gross tumor volume were assessed using a BNCT planning system.
  
  
  RESULTS
  The results are reported as median values with the interquartile range. In the IA group, the maximal, mean, and minimal dose given to the gross tumor volume was 68.7 Gy-Eq (range, 38.8-79.9), 45.0 Gy-Eq (range, 25.1-51.0), and 13.8 Gy-Eq (range, 4.8-25.3), respectively. In the IV group, the maximal, mean, and minimal dose given to the gross tumor volume was 24.2 Gy-Eq (range, 21.5-29.9), 16.4 Gy-Eq (range, 14.5-20.2), and 7.8 Gy-Eq (range, 6.8-9.5), respectively. Within 1-3 months after BNCT, the responses were assessed. Of the 6 patients in the IV group, 2 had a partial response, 3 no change, and 1 had progressive disease. Of 4 patients in the IA group, 1 achieved a complete response and 3 a partial response.
  
  
  CONCLUSIONS
  Intra-arterial administration of boronophenylalanine is a promising drug delivery system for head-and-neck BNCT.
authors.affiliation: Particle Oncology Research Center, Research Reactor Institute, Kyoto University, Osaka, Japan. msuzuki@rri.kyot-u.ac.jp
authors.forename: Minoru
authors.initials: M
authors.lastname: Suzuki
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Sakurai
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagata
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kinashi
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Masunaga
authors.forename: Koji
authors.initials: K
authors.lastname: Ono
authors.forename: Akira
authors.initials: A
authors.lastname: Maruhashi
authors.forename: Ituro
authors.initials: I
authors.lastname: Kato
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Fuwa
authors.forename: Junichi
authors.initials: J
authors.lastname: Hiratsuka
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Imahori
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001896:Boron Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D005260:Female; D006258:Head and Neck Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000532:radiotherapy*; D010649:Phenylalanine / Q000819:agonists* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D001896:Boron Compounds; D010649:Phenylalanine